Home » Unilife Signs First Supply Agreement With MedImmune
Unilife Signs First Supply Agreement With MedImmune
Unilife has signed the first supply agreement with MedImmune, the global biologics R&D arm of AstraZeneca.
Under the agreement, UniLife will supply its customized precision therapy platform of wearable injectors for a monoclonal antibody in late-stage clinical studies in MedImmune's portfolio.
The agreement follows the master terms from a November 2013 master development and supply agreement for the customization and supply of Unilife's wearable injectors for use with MedImmune's drug candidates. — Michael Cipriano
Upcoming Events
-
07May
-
14May
-
30May